Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Jan 2021 16:29

RNS Number : 8284K
Open Orphan PLC
06 January 2021
 

Standard Form TR-1

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the Central Bank of Ireland)i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Open Orphan PLC GB00B9275X97

LEI 213800VT5KBM7JLIV118

2. Reason for the notification (please tick the appropriate box or boxes):

[X] An acquisition or disposal of voting rights

[ ] An acquisition or disposal of financial instruments

[ ] An event changing the breakdown of voting rights

[ ] Other (please specify)iii:

3. Details of person subject to the notification obligationiv :

Name: Invesco Ltd.

City and country of registered office (if applicable):

1555 Peachtree Street NE, Suite 1800, Atlanta, GA 30309 United States.

4. Full name of shareholder(s) (if different from 3.)v:

 

5. Date on which the threshold was crossed or reachedvi:

04-01-2021

6. Date on which issuer notified:

06-01-2021

7. Threshold(s) that is/are crossed or reached:

5% reached

8. Total positions of person(s) subject to the notification obligation:

% of voting rights attached to shares (total of 9.A)

% of voting rights through financial instruments(total of 9.B.1 + 9.B.2)

Total of both in % (9.A + 9.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.96%

0%

5.96%

668,052,261

Position of previous notification (if applicable)

9.86%

0%

9.86%

 

9. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii:

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

 

Direct

 

 

Indirect

 

 

Direct

 

 

Indirect

 

GB00B9275X97

0

39,831,346

0

5.96%

SUBTOTAL A

39,831,346

5.96%

B 1: Financial Instruments according to Regulation 17(1)(a) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

SUBTOTAL B.1

B 2: Financial Instruments with similar economic effect according to Regulation 17(1)(b) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash settlementxii

Number of voting rights

% of voting rights

SUBTOTAL B.2

 

10. Information in relation to the person subject to the notification obligation (please tick the applicable box):

 

[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii

 

[X] Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Invesco Asset Management Limited

5.96%

0%

5.96%

11. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

 

 

12. Additional informationxvi:

Click here to enter text.

 

Done at Henley-on-Thames on 06-01-2021

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBLGDBLDGDGBL
Date   Source Headline
17th Feb 202212:05 pmRNSPositive results from RSV Human Challenge Study
14th Feb 20227:00 amRNSLaunch of STRiVE project
2nd Feb 20227:00 amRNSWorld’s first COVID-19 Characterisation Study
26th Jan 20224:40 pmRNSSecond Price Monitoring Extn
26th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSMalaria Human Challenge Model Launched
21st Dec 20217:00 amRNS£5m Influenza human challenge study contract win
16th Dec 20214:41 pmRNSSecond Price Monitoring Extn
16th Dec 20214:35 pmRNSPrice Monitoring Extension
10th Dec 202111:05 amRNSSecond Price Monitoring Extn
10th Dec 202111:00 amRNSPrice Monitoring Extension
10th Dec 20217:05 amRNSExercise of Options
10th Dec 20217:00 amRNS$13.4m Influenza HCS contract win
6th Dec 20217:00 amRNSPositive results from Flu Human Challenge Study
19th Nov 20217:00 amRNSImutex Vaccine Phase I Study Results
17th Nov 20217:00 amRNS£5.1m RSV contract
15th Nov 20217:00 amRNS£1.5m Contract renewal for Venn Life Sciences
13th Oct 20217:00 amRNSDirectorate Change
20th Sep 20217:00 amRNSHalf-year Report
20th Sep 20217:00 amRNS£5.7m Influenza human challenge study contract win
9th Sep 20217:00 amRNSNotice of Results
7th Sep 20217:00 amRNSPositive results from RSV Human Challenge Study
24th Aug 20219:05 amRNSSecond Price Monitoring Extn
24th Aug 20219:00 amRNSPrice Monitoring Extension
24th Aug 20217:00 amRNS£8.1m Asthma Human Challenge Study Contract Win
9th Aug 20217:00 amRNSMalaria Human Challenge Model
29th Jul 20217:00 amRNSDNDi Phase II trial support
22nd Jul 20217:00 amRNSNEJM Opinion Piece
21st Jul 202112:58 pmRNSResult of AGM
14th Jul 20219:06 amRNSDirectors’ Dealings
14th Jul 20218:04 amRNSAIM Schedule 1 update by Poolbeg Pharma plc
14th Jul 20217:01 amRNSNew Contract win for Open Orphan’s Breda office
14th Jul 20217:00 amRNSCOVID-19 Human Challenge Programme update
9th Jul 20217:00 amRNSHRV and Flu contract
7th Jul 20214:41 pmRNSSecond Price Monitoring Extn
7th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jun 20217:00 amRNS2020 Annual Report and 2021 AGM Notice
17th Jun 20217:00 amRNSFinal Results to 31 December 2020
17th Jun 20217:00 amRNSDemerger Update
14th Jun 20217:00 amRNSRe. Distribution in Specie and Notice of Results
11th Jun 20217:00 amRNSExercise of Warrants
19th May 20217:00 amRNSCourt Approval
10th May 20217:15 amRNSExercise of Share Options
10th May 20217:00 amRNS£3m COVID challenge virus manufacturing contract
29th Apr 202111:39 amRNSResult of General Meeting
13th Apr 20217:00 amRNSPotential demerger of certain non-core assets
9th Apr 20217:00 amRNSLaunch of Disease in Motion platform
31st Mar 20217:00 amRNSHolding(s) in Company
26th Mar 20217:00 amRNS£7.5m Human Challenge Study Contract
25th Mar 20217:00 amRNSCOVID-19 Human Challenge Programme update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.